Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
CA 2348281 A1 · Owner: Janus Pharmaceuticals, Inc. · Inventors: Klein, Donald F.; Landry, Donald W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are disclosed utilizing the R enantiomer of tofisopam. This compound is useful in the treatment or prevention of anxiety or anxiety disorders while substantially reducing adverse effects associated with racemic tofisopam.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 27, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 27, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 27, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.